Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,9.8,2734,DB01338,Pipecuronium
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,77.7,2735,DB01338,Pipecuronium
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,7.2,2736,DB01338,Pipecuronium
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,"100, 6",2737,DB01338,Pipecuronium
,2848702,Vd,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg],362.3,2738,DB01338,Pipecuronium
,2848702,Vd,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg],123.7,2739,DB01338,Pipecuronium
,2848702,clearance,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg·min],5.0,2740,DB01338,Pipecuronium
,2848702,clearance,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [min],1.0,2741,DB01338,Pipecuronium
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],309,32109,DB01338,Pipecuronium
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],442,32110,DB01338,Pipecuronium
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32111,DB01338,Pipecuronium
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32112,DB01338,Pipecuronium
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,140,32113,DB01338,Pipecuronium
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,329,32114,DB01338,Pipecuronium
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,137,32115,DB01338,Pipecuronium
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,263,32116,DB01338,Pipecuronium
,2536254,volume of distribution at steady state,"The same parameters as derived by the non-compartmental method were (normal vs. renal failure, respectively): volume of distribution at steady state (307 +/- 80 vs.",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),,307,32117,DB01338,Pipecuronium
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32118,DB01338,Pipecuronium
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32119,DB01338,Pipecuronium
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,134,32120,DB01338,Pipecuronium
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,323,32121,DB01338,Pipecuronium
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,118,32122,DB01338,Pipecuronium
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,247,32123,DB01338,Pipecuronium
,1662599,Onset time,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.3,57479,DB01338,Pipecuronium
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,109,57480,DB01338,Pipecuronium
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.8,57481,DB01338,Pipecuronium
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,39,57482,DB01338,Pipecuronium
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,101.5,57483,DB01338,Pipecuronium
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,179,57484,DB01338,Pipecuronium
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.339,57485,DB01338,Pipecuronium
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.506,57486,DB01338,Pipecuronium
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],3.4,57487,DB01338,Pipecuronium
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],2.5,57488,DB01338,Pipecuronium
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,2.54,61380,DB01338,Pipecuronium
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,2.04,61381,DB01338,Pipecuronium
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,5.75,61382,DB01338,Pipecuronium
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],1.50,61383,DB01338,Pipecuronium
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],2.27,61384,DB01338,Pipecuronium
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],2.45,61385,DB01338,Pipecuronium
,2849968,steady-state volume of distribution (Vss),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],309,100901,DB01338,Pipecuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],2.4,100902,DB01338,Pipecuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],199,100903,DB01338,Pipecuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],1.5,100904,DB01338,Pipecuronium
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,98.0,100905,DB01338,Pipecuronium
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,117.2,100906,DB01338,Pipecuronium
,19468626,Time for T1 < 10%,"Time for T1 < 10% was 161.4 +/- 13.7 seconds for Group 1 and 217.8 +/- 23.4 seconds for Group 2, with p < 0.001 and statistically significant differences between groups.","Effect of priming in shortening onset of pipecuronium, a new nondepolarizing neuromuscular blocker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19468626/),seconds,161.4,133610,DB01338,Pipecuronium
,19468626,Time for T1 < 10%,"Time for T1 < 10% was 161.4 +/- 13.7 seconds for Group 1 and 217.8 +/- 23.4 seconds for Group 2, with p < 0.001 and statistically significant differences between groups.","Effect of priming in shortening onset of pipecuronium, a new nondepolarizing neuromuscular blocker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19468626/),seconds,217.8,133611,DB01338,Pipecuronium
,2556065,distribution half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,3.9,138380,DB01338,Pipecuronium
,2556065,distribution half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,12.7,138381,DB01338,Pipecuronium
,2556065,elimination half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,44.8,138382,DB01338,Pipecuronium
,2556065,elimination half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,196.7,138383,DB01338,Pipecuronium
,2556065,elimination half-life,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,196.7,138384,DB01338,Pipecuronium
,2556065,elimination half-life,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,44.8,138385,DB01338,Pipecuronium
,2556065,plasma clearance,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),[ml] / [kg·min],5.9,138386,DB01338,Pipecuronium
,2556065,plasma clearance,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),[ml] / [kg·min],0.9,138387,DB01338,Pipecuronium
,2556065,mean residence time,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,221,138388,DB01338,Pipecuronium
,2556065,mean residence time,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,51.1,138389,DB01338,Pipecuronium
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),,77,138390,DB01338,Pipecuronium
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),%,4.5,138391,DB01338,Pipecuronium
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),%,3,138392,DB01338,Pipecuronium
,1976829,T1/2 alpha,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,3.9,158846,DB01338,Pipecuronium
,1976829,T1/2 beta,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,102,158847,DB01338,Pipecuronium
,1976829,V1,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],95,158848,DB01338,Pipecuronium
,1976829,Vdss,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],264,158849,DB01338,Pipecuronium
,1976829,Cl,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.8,158850,DB01338,Pipecuronium
,1976829,V1,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],38,158851,DB01338,Pipecuronium
,1976829,Vdss,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],120,158852,DB01338,Pipecuronium
,1976829,Cl,"Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.1,158853,DB01338,Pipecuronium
,1323914,elimination half-life,"The elimination half-life in animals was found to be around 40 min, in humans between 44-137 min.",[Pharmacokinetics and metabolism of pipecuronium bromide (Arduan)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1323914/),min,40,193557,DB01338,Pipecuronium
,1323914,elimination half-life,"The elimination half-life in animals was found to be around 40 min, in humans between 44-137 min.",[Pharmacokinetics and metabolism of pipecuronium bromide (Arduan)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1323914/),min,44-137,193558,DB01338,Pipecuronium
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,6.9,195672,DB01338,Pipecuronium
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,4.3,195673,DB01338,Pipecuronium
,2155718,t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,7.6,199052,DB01338,Pipecuronium
,2155718,terminal phase (t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,161,199053,DB01338,Pipecuronium
,2155718,central compartment volume,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg],102,199054,DB01338,Pipecuronium
,2155718,plasma clearance,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg·min],1.8,199055,DB01338,Pipecuronium
,6274362,T 1/2 alpha,The average half-lives were T 1/2 alpha = 4.1 +/- 1.4 (n = 8) and T 1/2 beta = 44 +/- 7 (n = 8) min.,"Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),min,4.1,215002,DB01338,Pipecuronium
,6274362,T 1/2 beta,The average half-lives were T 1/2 alpha = 4.1 +/- 1.4 (n = 8) and T 1/2 beta = 44 +/- 7 (n = 8) min.,"Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),min,44,215003,DB01338,Pipecuronium
,6274362,apparent distribution volume V beta,"The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume V beta = 261 +/- 28 (n = 8) ml/kg, plasma clearance Cl = 320 +/- 55 (n = 8) ml/min.","Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),[ml] / [kg],261,215004,DB01338,Pipecuronium
,6274362,plasma clearance Cl,"The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume V beta = 261 +/- 28 (n = 8) ml/kg, plasma clearance Cl = 320 +/- 55 (n = 8) ml/min.","Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),[ml] / [min],320,215005,DB01338,Pipecuronium
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.96,215622,DB01338,Pipecuronium
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.61,215623,DB01338,Pipecuronium
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,111,215624,DB01338,Pipecuronium
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,143,215625,DB01338,Pipecuronium
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],350,215626,DB01338,Pipecuronium
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],452,215627,DB01338,Pipecuronium
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,233,215628,DB01338,Pipecuronium
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,170,215629,DB01338,Pipecuronium
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB01338,Pipecuronium
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB01338,Pipecuronium
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB01338,Pipecuronium
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB01338,Pipecuronium
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB01338,Pipecuronium
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB01338,Pipecuronium
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB01338,Pipecuronium
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB01338,Pipecuronium
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB01338,Pipecuronium
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB01338,Pipecuronium
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB01338,Pipecuronium
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB01338,Pipecuronium
,6248080,Binding,Binding to rat plasma protein is of about 30%.,Disposition of pipecurium bromide in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,30,263038,DB01338,Pipecuronium
,6248080,excreted amount,"The compound seems to be eliminated with urine, the excreted amount being 37.55 +/- 11.91% and 45.44 +/- 17.29% during 24 and 48 h, respectively.",Disposition of pipecurium bromide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,37.55,263039,DB01338,Pipecuronium
,6248080,excreted amount,"The compound seems to be eliminated with urine, the excreted amount being 37.55 +/- 11.91% and 45.44 +/- 17.29% during 24 and 48 h, respectively.",Disposition of pipecurium bromide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,45.44,263040,DB01338,Pipecuronium
